Clin Pharmacokinet. 2026 Jan 27. doi: 10.1007/s40262-025-01617-x. Online ahead of print.
ABSTRACT
BACKGROUND AND OBJECTIVE: Accurate assessment of the glomerular filtration rate (GFR) is crucial in critically ill children, yet standard estimation formulas (eGFR) perform poorly, especially in the youngest. Iohexol plasma clearance is the reference standard for measured GFR; however, its routine use is limited by logistical constraints. This study aims to develop and internally validate a population pharmacokinetic model of iohexol in critically ill children, to derive a practical model-based GFR estimation formula (eGFRiohexol), and to compare its predictive performance against established eGFR formulas (eGFRSchwartz, eGFRSmeets/Pierce).
METHODS: After administration of iohexol, up to six blood samples were drawn from 107 patients over a 6-hour interval. Data from 93 patients were used for model building, and from 31 patients for internal validation. Reference clearances were obtained using the post hoc Bayesian clearance estimates. Predictive performances of eGFRiohexol, eGFRSchwartz, and eGFRSmeets/Pierce were compared with reference clearances using bias, imprecision, Total Deviation Index, concordance correlation coefficient, and the percentage of predictions within 10 and 30% error (P10, P30) around reference clearances.
RESULTS: The final model identified body surface area, serum creatinine, cystatin C, postoperative status, and clonidine treatment as significant predictors of iohexol clearance. eGFRiohexol demonstrated minimal bias (-0.8%) and imprecision (21%) and high accuracy (P30 = 87%), particularly in patients under 2 years of age (P30 = 90 vs 40% for eGFRSchwartz). Furthermore, eGFRiohexol also demonstrated superiority over eGFRSmeets/Pierce, which exhibited moderate bias (-5.4%) and reduced accuracy (P30 = 68%).
CONCLUSIONS: A model-derived GFR estimation formula based on iohexol population pharmacokinetic modeling might allow for an accurate bedside assessment of kidney function in critically ill children, outperforming the Schwartz and Smeets/Pierce formulas, particularly in infants. External validation in larger pediatric intensive care unit populations, across the full age and GFR range, is warranted to confirm the generalizability of this equation and its potential for broader clinical application.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT05179564, registered retrospectively on 5 January, 2022.
PMID:41591642 | DOI:10.1007/s40262-025-01617-x